This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zurenko, G. E.
Right arrow Articles by Brickner, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zurenko, G. E.
Right arrow Articles by Brickner, S. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 04 1996, 839-845, Vol 40, No. 4
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

GE Zurenko, BH Yagi, RD Schaadt, JW Allison, JO Kilburn, SE Glickman, DK Hutchinson, MR Barbachyn and SJ Brickner
Pharmacia & Upjohn, Inc., Kalamazoo, Michigan 49001, USA.

Oxazolidinones make up a relatively new class of antimicrobial agents which possess a unique mechanism of bacterial protein synthesis inhibition. U-100592 (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1- piperazinyl]- phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide and U- 100766 (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]- 2-oxo-5- oxazolidinyl]methyl]-acetamide are novel oxazolidinone analogs from a directed chemical modification program. MICs were determined for a variety of bacterial clinical isolates; the respective MICs of U-100592 and U-100766 at which 90% of isolates are inhibited were as follows: methicillin-susceptible Staphylococcus aureus, 4 and 4 micrograms/ml; methicillin-resistant S. aureus, 4 and 4 micrograms/ml; methicillin- susceptible Staphylococcus epidermidis, 2 and 2 micrograms/ml; methicillin-resistant S. epidermidis, 1 and 2 micrograms/ml; Enterococcus faecalis, 2 and 4 micrograms/ml; Enterococcus faecium, 2 and 4 micrograms/ml; Streptococcus pyogenes, 1 and 2 micrograms/ml; Streptococcus pneumoniae, 0.50 and 1 microgram/ml; Corynebacterium spp., 0.50 and 0.50 micrograms/ml; Moraxella catarrhalis, 4 and 4 micrograms/ml; Listeria monocytogenes, 8 and 2 micrograms/ml; and Bacteroides fragilis, 16 and 4 micrograms/ml. Most strains of Mycobacterium tuberculosis and the gram-positive anaerobes were inhibited in the range of 0.50 to 2 micrograms/ml. Enterococcal strains resistant to vancomycin (VanA, VanB, and VanC resistance phenotypes), pneumococcal strains resistant to penicillin, and M. tuberculosis strains resistant to common antitubercular agents (isoniazid, streptomycin, rifampin, ethionamide, and ethambutol) were not cross- resistant to the oxazolidinones. The presence of 10, 20, and 40% pooled human serum did not affect the antibacterial activities of the oxazolidinones. Time-kill studies demonstrated a bacteriostatic effect of the analogs against staphylococci and enterococci but a bactericidal effect against streptococci. The spontaneous mutation frequencies of S. aureus ATCC 29213 were <3.8 x 10(-10) and <8 x 10(-11) for U-100592 and U-100766, respectively. Serial transfer of three staphylococcal and two enterococcal strains on drug gradient plates produced no evidence of rapid resistance development. Thus, these new oxazolidinone analogs demonstrated in vitro antibacterial activities against a variety of clinically important human pathogens.


This article has been cited by other articles:

  • Locke, J. B., Hilgers, M., Shaw, K. J. (2009). Novel Ribosomal Mutations in Staphylococcus aureus Strains Identified through Selection with the Oxazolidinones Linezolid and Torezolid (TR-700). Antimicrob. Agents Chemother. 53: 5265-5274 [Abstract] [Full Text]  
  • Paul-Satyaseela, M., Solanki, S. S., Sathishkumar, D., Bharani, T., Magesh, V., Rajagopal, S. (2009). In vitro antibacterial activities of a novel oxazolidinone, OCID0050. J Antimicrob Chemother 64: 797-800 [Abstract] [Full Text]  
  • Abe, S., Chiba, K., Cirincione, B., Grasela, T. H., Ito, K., Suwa, T. (2009). Population Pharmacokinetic Analysis of Linezolid in Patients With Infectious Disease: Application to Lower Body Weight and Elderly Patients. J Clin Pharmacol 49: 1071-1078 [Abstract] [Full Text]  
  • Shaw, K. J., Poppe, S., Schaadt, R., Brown-Driver, V., Finn, J., Pillar, C. M., Shinabarger, D., Zurenko, G. (2008). In Vitro Activity of TR-700, the Antibacterial Moiety of the Prodrug TR-701, against Linezolid-Resistant Strains. Antimicrob. Agents Chemother. 52: 4442-4447 [Abstract] [Full Text]  
  • Dietze, R., Hadad, D. J., McGee, B., Molino, L. P. D., Maciel, E. L. N., Peloquin, C. A., Johnson, D. F., Debanne, S. M., Eisenach, K., Boom, W. H., Palaci, M., Johnson, J. L. (2008). Early and Extended Early Bactericidal Activity of Linezolid in Pulmonary Tuberculosis. Am. J. Respir. Crit. Care Med. 178: 1180-1185 [Abstract] [Full Text]  
  • Condos, R., Hadgiangelis, N., Leibert, E., Jacquette, G., Harkin, T., Rom, W. N. (2008). Case Series Report of a Linezolid-Containing Regimen for Extensively Drug-Resistant Tuberculosis. Chest 134: 187-192 [Abstract] [Full Text]  
  • Arias, C. A., Vallejo, M., Reyes, J., Panesso, D., Moreno, J., Castaneda, E., Villegas, M. V., Murray, B. E., Quinn, J. P. (2008). Clinical and Microbiological Aspects of Linezolid Resistance Mediated by the cfr Gene Encoding a 23S rRNA Methyltransferase. J. Clin. Microbiol. 46: 892-896 [Abstract] [Full Text]  
  • Schmidt, S., Banks, R., Kumar, V., Rand, K. H., Derendorf, H. (2008). Clinical Microdialysis in Skin and Soft Tissues: An Update. J Clin Pharmacol 48: 351-364 [Abstract] [Full Text]  
  • Attwood, R. J., LaPlante, K. L. (2007). Telavancin: A novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 64: 2335-2348 [Abstract] [Full Text]  
  • de Jesus Valle, M. J., Uranga, N. S., Lopez, F. G., Hurle, A. D.-G., Navarro, A. S. (2007). Disposition of linezolid in the isolated rat lung after systemic and pulmonary drug delivery. J Antimicrob Chemother 60: 1074-1079 [Abstract] [Full Text]  
  • Tenover, F. C., Williams, P. P., Stocker, S., Thompson, A., Clark, L. A., Limbago, B., Carey, R. B., Poppe, S. M., Shinabarger, D., McGowan, J. E. Jr. (2007). Accuracy of Six Antimicrobial Susceptibility Methods for Testing Linezolid against Staphylococci and Enterococci. J. Clin. Microbiol. 45: 2917-2922 [Abstract] [Full Text]  
  • French, G. L. (2006). Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin. J Antimicrob Chemother 58: 1107-1117 [Abstract] [Full Text]  
  • Daeschlein, G., Hoehne, C., Assadian, O., Daxboeck, F., Meinl, C., Kramer, A., Kekule, A.S. (2006). In vitro activity of linezolid against clinical isolates of Fusobacterium spp.. J Antimicrob Chemother 58: 789-793 [Abstract] [Full Text]  
  • Jones, R. N., Ross, J. E., Fritsche, T. R., Sader, H. S. (2006). Oxazolidinone susceptibility patterns in 2004: report from the Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 57: 279-287 [Abstract] [Full Text]  
  • Draghi, D. C., Sheehan, D. J., Hogan, P., Sahm, D. F. (2005). In Vitro Activity of Linezolid against Key Gram-Positive Organisms Isolated in the United States: Results of the LEADER 2004 Surveillance Program. Antimicrob. Agents Chemother. 49: 5024-5032 [Abstract] [Full Text]  
  • Fujikawa, K., Chiba, M., Tanaka, M., Sato, K. (2005). In Vitro Antibacterial Activity of DX-619, a Novel Des-Fluoro(6) Quinolone. Antimicrob. Agents Chemother. 49: 3040-3045 [Abstract] [Full Text]  
  • Dehghanyar, P., Burger, C., Zeitlinger, M., Islinger, F., Kovar, F., Muller, M., Kloft, C., Joukhadar, C. (2005). Penetration of Linezolid into Soft Tissues of Healthy Volunteers after Single and Multiple Doses. Antimicrob. Agents Chemother. 49: 2367-2371 [Abstract] [Full Text]  
  • Kosowska, K., Hoellman, D. B., Lin, G., Clark, C., Credito, K., McGhee, P., Dewasse, B., Bozdogan, B., Shapiro, S., Appelbaum, P. C. (2005). Antipneumococcal Activity of Ceftobiprole, a Novel Broad-Spectrum Cephalosporin. Antimicrob. Agents Chemother. 49: 1932-1942 [Abstract] [Full Text]  
  • Jacqueline, C., Navas, D., Batard, E., Miegeville, A.-F., Le Mabecque, V., Kergueris, M.-F., Bugnon, D., Potel, G., Caillon, J. (2005). In Vitro and In Vivo Synergistic Activities of Linezolid Combined with Subinhibitory Concentrations of Imipenem against Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 45-51 [Abstract] [Full Text]  
  • Abbanat, D., Webb, G., Foleno, B., Li, Y., Macielag, M., Montenegro, D., Wira, E., Bush, K. (2005). In Vitro Activities of Novel 2-Fluoro-Naphthyridine-Containing Ketolides. Antimicrob. Agents Chemother. 49: 309-315 [Abstract] [Full Text]  
  • Bosso, J. A., Flume, P. A., Gray, S. L. (2004). Linezolid Pharmacokinetics in Adult Patients with Cystic Fibrosis. Antimicrob. Agents Chemother. 48: 281-284 [Abstract] [Full Text]  
  • Yong, D., Yum, J. H., Lee, K., Chong, Y., Choi, S. H., Rhee, J. K. (2004). In Vitro Activities of DA-7867, a Novel Oxazolidinone, against Recent Clinical Isolates of Aerobic and Anaerobic Bacteria. Antimicrob. Agents Chemother. 48: 352-357 [Abstract] [Full Text]  
  • Turner, J. M, Hakeem, L. M, Lockman, K A., Bhattacharyya, D. N, Campbell, I. W (2004). Diabetic MRSA foot infection -- role of linezolid therapy. British Journal of Diabetes & Vascular Disease 4: 44-46 [Abstract]  
  • Wagenlehner, F. M. E., Wydra, S., Onda, H., Kinzig-Schippers, M., Sorgel, F., Naber, K. G. (2003). Concentrations in Plasma, Urinary Excretion, and Bactericidal Activity of Linezolid (600 Milligrams) versus Those of Ciprofloxacin (500 Milligrams) in Healthy Volunteers Receiving a Single Oral Dose. Antimicrob. Agents Chemother. 47: 3789-3794 [Abstract] [Full Text]  
  • Brier, M. E., Stalker, D. J., Aronoff, G. R., Batts, D. H., Ryan, K. K., O'Grady, M., Hopkins, N. K., Jungbluth, G. L. (2003). Pharmacokinetics of Linezolid in Subjects with Renal Dysfunction. Antimicrob. Agents Chemother. 47: 2775-2780 [Abstract] [Full Text]  
  • Alloush, H. M., Salisbury, V., Lewis, R. J., MacGowan, A. P. (2003). Pharmacodynamics of linezolid in a clinical isolate of Streptococcus pneumoniae genetically modified to express lux genes. J Antimicrob Chemother 52: 511-513 [Abstract] [Full Text]  
  • Rubinstein, E., Isturiz, R., Standiford, H. C., Smith, L. G., Oliphant, T. H., Cammarata, S., Hafkin, B., Le, V., Remington, J. (2003). Worldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III Studies. Antimicrob. Agents Chemother. 47: 1824-1831 [Abstract] [Full Text]  
  • Sweeney, M. T., Zurenko, G. E. (2003). In Vitro Activities of Linezolid Combined with Other Antimicrobial Agents against Staphylococci, Enterococci, Pneumococci, and Selected Gram-Negative Organisms. Antimicrob. Agents Chemother. 47: 1902-1906 [Abstract] [Full Text]  
  • Stalker, D. J., Jungbluth, G. L., Hopkins, N. K., Batts, D. H. (2003). Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 51: 1239-1246 [Abstract] [Full Text]  
  • Humphrey, W. R., Shattuck, M. H., Zielinski, R. J., Kuo, M.-S. T., Biermacher, J. J., Smith, D. P., Jensen, J. L., Schaadt, R. D., Zurenko, G. E., Richards, I. M. (2003). Pharmacokinetics and Efficacy of Linezolid in a Gerbil Model of Streptococcus pneumoniae-Induced Acute Otitis Media. Antimicrob. Agents Chemother. 47: 1355-1363 [Abstract] [Full Text]  
  • Jacqueline, C., Caillon, J., Le Mabecque, V., Miegeville, A.-F., Donnio, P.-Y., Bugnon, D., Potel, G. (2003). In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 51: 857-864 [Abstract] [Full Text]  
  • Moellering, R. C. Jr. (2003). Linezolid: The First Oxazolidinone Antimicrobial. ANN INTERN MED 138: 135-142 [Abstract] [Full Text]  
  • Alcala, L., Ruiz-Serrano, M. J., Perez-Fernandez Turegano, C., Garcia de Viedma, D., Diaz-Infantes, M., Marin-Arriaza, M., Bouza, E. (2003). In Vitro Activities of Linezolid against Clinical Isolates of Mycobacterium tuberculosis That Are Susceptible or Resistant to First-Line Antituberculous Drugs. Antimicrob. Agents Chemother. 47: 416-417 [Abstract] [Full Text]  
  • Grohs, P., Kitzis, M.-D., Gutmann, L. (2003). In Vitro Bactericidal Activities of Linezolid in Combination with Vancomycin, Gentamicin, Ciprofloxacin, Fusidic Acid, and Rifampin against Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 418-420 [Abstract] [Full Text]  
  • Jacqueline, C., Batard, E., Perez, L., Boutoille, D., Hamel, A., Caillon, J., Kergueris, M.-F., Potel, G., Bugnon, D. (2002). In Vivo Efficacy of Continuous Infusion versus Intermittent Dosing of Linezolid Compared to Vancomycin in a Methicillin-Resistant Staphylococcus aureus Rabbit Endocarditis Model. Antimicrob. Agents Chemother. 46: 3706-3711 [Abstract] [Full Text]  
  • Pascual, A., Ballesta, S., Garcia, I., Perea, E. J. (2002). Uptake and Intracellular Activity of Linezolid in Human Phagocytes and Nonphagocytic Cells. Antimicrob. Agents Chemother. 46: 4013-4015 [Abstract] [Full Text]  
  • Burkhardt, O., Borner, K., von der Hoh, N., Koppe, P., Pletz, M. W., Nord, C. E., Lode, H. (2002). Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. J Antimicrob Chemother 50: 707-712 [Abstract] [Full Text]  
  • Gerson, S. L., Kaplan, S. L., Bruss, J. B., Le, V., Arellano, F. M., Hafkin, B., Kuter, D. J. (2002). Hematologic Effects of Linezolid: Summary of Clinical Experience. Antimicrob. Agents Chemother. 46: 2723-2726 [Abstract] [Full Text]  
  • Karlowsky, J. A., Kelly, L. J., Critchley, I. A., Jones, M. E., Thornsberry, C., Sahm, D. F. (2002). Determining Linezolid's Baseline In Vitro Activity in Canada Using Gram-Positive Clinical Isolates Collected prior to Its National Release. Antimicrob. Agents Chemother. 46: 1989-1992 [Abstract] [Full Text]  
  • Low, D. E., de Azavedo, J., Weiss, K., Mazzulli, T., Kuhn, M., Church, D., Forward, K., Zhanel, G., Simor, A., McGeer, A. (2002). Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob. Agents Chemother. 46: 1295-1301 [Abstract] [Full Text]  
  • Gentry-Nielsen, M. J., Olsen, K. M., Preheim, L. C. (2002). Pharmacodynamic Activity and Efficacy of Linezolid in a Rat Model of Pneumococcal Pneumonia. Antimicrob. Agents Chemother. 46: 1345-1351 [Abstract] [Full Text]  
  • Conte, J. E. Jr., Golden, J. A., Kipps, J., Zurlinden, E. (2002). Intrapulmonary Pharmacokinetics of Linezolid. Antimicrob. Agents Chemother. 46: 1475-1480 [Abstract] [Full Text]  
  • Gershon, A. S., de Azavedo, J. C. S., McGeer, A., Ostrowska, K. I., Church, D., Hoban, D. J., Harding, G. K. M., Weiss, K., Abbott, L., Smaill, F., Gourdeau, M., Murray, G., Low, D. E. (2002). Activities of New Fluoroquinolones, Ketolides, and Other Antimicrobials against Blood Culture Isolates of Viridans Group Streptococci from across Canada, 2000. Antimicrob. Agents Chemother. 46: 1553-1556 [Abstract] [Full Text]  
  • Zhou, C. C., Swaney, S. M., Shinabarger, D. L., Stockman, B. J. (2002). 1H Nuclear Magnetic Resonance Study of Oxazolidinone Binding to Bacterial Ribosomes. Antimicrob. Agents Chemother. 46: 625-629 [Abstract] [Full Text]  
  • Gander, S., Hayward, K., Finch, R. (2002). An investigation of the antimicrobial effects of linezolid on bacterial biofilms utilizing an in vitro pharmacokinetic model. J Antimicrob Chemother 49: 301-308 [Abstract] [Full Text]  
  • Szczypa, K., Betlejewska, K., Nowak, K., Hryniewicz, K. (2001). In vitro activity of linezolid against Gram-positive cocci isolated in Poland. J Antimicrob Chemother 48: 932-935 [Full Text]  
  • Vera-Cabrera, L., Gomez-Flores, A., Escalante-Fuentes, W. G., Welsh, O. (2001). In Vitro Activity of PNU-100766 (Linezolid), a New Oxazolidinone Antimicrobial, against Nocardia brasiliensis. Antimicrob. Agents Chemother. 45: 3629-3630 [Abstract] [Full Text]  
  • Livermore, D. M., Mushtaq, S., Warner, M. (2001). Susceptibility testing with linezolid by different methods, in relation to published 'general breakpoints': J Antimicrob Chemother 2001; 48: 452-454. J Antimicrob Chemother 48: 452-454 [Full Text]  
  • (2001). {blacktriangledown}Linezolid for Gram-positive infections. DTB 39: 54-56 [Abstract] [Full Text]  
  • Gemmell, C. G., participating investigators in France, Germany, Ho, o. b. o. (2001). Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison. J Antimicrob Chemother 48: 47-52 [Abstract] [Full Text]  
  • Zaoutis, T., Moore, L. S., Furness, K., Klein, J. D. (2001). In Vitro Activities of Linezolid, Meropenem, and Quinupristin-Dalfopristin against Group C and G Streptococci, Including Vancomycin-Tolerant Isolates. Antimicrob. Agents Chemother. 45: 1952-1954 [Abstract] [Full Text]  
  • Prystowsky, J., Siddiqui, F., Chosay, J., Shinabarger, D. L., Millichap, J., Peterson, L. R., Noskin, G. A. (2001). Resistance to Linezolid: Characterization of Mutations in rRNA and Comparison of Their Occurrences in Vancomycin-Resistant Enterococci. Antimicrob. Agents Chemother. 45: 2154-2156 [Abstract] [Full Text]  
  • Gee, T., Ellis, R., Marshall, G., Andrews, J., Ashby, J., Wise, R. (2001). Pharmacokinetics and Tissue Penetration of Linezolid following Multiple Oral Doses. Antimicrob. Agents Chemother. 45: 1843-1846 [Abstract] [Full Text]  
  • O'Neill, A. J., Chopra, I., Martínez, J. L., Baquero, F. (2001). Use of Mutator Strains for Characterization of Novel Antimicrobial Agents. Antimicrob. Agents Chemother. 45: 1599-1600 [Full Text]  
  • Oramas-Shirey, M. P., Buchanan, L. V., Dileto-Fang, C. L., Dailey, C. F., Ford, C. W., Batts, D. H., Gibson, J. K. (2001). Efficacy of linezolid in a staphylococcal endocarditis rabbit model. J Antimicrob Chemother 47: 349-352 [Abstract] [Full Text]  
  • Stevens, D. L., Smith, L. G., Bruss, J. B., McConnell-Martin, M. A., Duvall, S. E., Todd, W. M., Hafkin, B. (2000). Randomized Comparison of Linezolid (PNU-100766) versus Oxacillin-Dicloxacillin for Treatment of Complicated Skin and Soft Tissue Infections. Antimicrob. Agents Chemother. 44: 3408-3413 [Abstract] [Full Text]  
  • Xiong, L., Kloss, P., Douthwaite, S., Andersen, N. M., Swaney, S., Shinabarger, D. L., Mankin, A. S. (2000). Oxazolidinone Resistance Mutations in 23S rRNA of Escherichia coli Reveal the Central Region of Domain V as the Primary Site of Drug Action. J. Bacteriol. 182: 5325-5331 [Abstract] [Full Text]  
  • Betriu, C., Redondo, M., Palau, M. L., Sánchez, A., Gómez, M., Culebras, E., Boloix, A., Picazo, J. J. (2000). Comparative In Vitro Activities of Linezolid, Quinupristin-Dalfopristin, Moxifloxacin, and Trovafloxacin against Erythromycin-Susceptible and -Resistant Streptococci. Antimicrob. Agents Chemother. 44: 1838-1841 [Abstract] [Full Text]  
  • Hirschl, A. M., Apfalter, P., Makristathis, A., Rotter, M. L., Wimmer, M. (2000). In Vitro Activities of Linezolid Alone and in Combination with Amoxicillin, Clarithromycin, and Metronidazole against Helicobacter pylori. Antimicrob. Agents Chemother. 44: 1977-1979 [Abstract] [Full Text]  
  • Fines, M., Leclercq, R. (2000). Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors. J Antimicrob Chemother 45: 797-802 [Abstract] [Full Text]  
  • Bowersock, T. L., Salmon, S. A., Portis, E. S., Prescott, J. F., Robison, D. A., Ford, C. W., Watts, J. L. (2000). MICs of Oxazolidinones for Rhodococcus equi Strains Isolated from Humans and Animals. Antimicrob. Agents Chemother. 44: 1367-1369 [Abstract] [Full Text]  
  • Schülin, T., Thauvin-Eliopoulos, C., Moellering, R. C. Jr., Eliopoulos, G. M. (1999). Activities of the Oxazolidinones Linezolid and Eperezolid in Experimental Intra-Abdominal Abscess Due to Enterococcus faecalis or Vancomycin-Resistant Enterococcus faecium. Antimicrob. Agents Chemother. 43: 2873-2876 [Abstract] [Full Text]  
  • Noskin, G. A., Siddiqui, F., Stosor, V., Hacek, D., Peterson, L. R. (1999). In Vitro Activities of Linezolid against Important Gram-Positive Bacterial Pathogens Including Vancomycin-Resistant Enterococci. Antimicrob. Agents Chemother. 43: 2059-2062 [Abstract] [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Merriam, C. V. (1999). Linezolid Activity Compared to Those of Selected Macrolides and Other Agents against Aerobic and Anaerobic Pathogens Isolated from Soft Tissue Bite Infections in Humans. Antimicrob. Agents Chemother. 43: 1469-1474 [Abstract] [Full Text]  
  • Cynamon, M. H., Klemens, S. P., Sharpe, C. A., Chase, S. (1999). Activities of Several Novel Oxazolidinones against Mycobacterium tuberculosis in a Murine Model. Antimicrob. Agents Chemother. 43: 1189-1191 [Abstract] [Full Text]  
  • Moellering, R. C. Jr. (1999). A Novel Antimicrobial Agent Joins the Battle against Resistant Bacteria. ANN INTERN MED 130: 155-157 [Full Text]  
  • Swaney, S. M., Aoki, H., Ganoza, M. C., Shinabarger, D. L. (1998). The Oxazolidinone Linezolid Inhibits Initiation of Protein Synthesis in Bacteria. Antimicrob. Agents Chemother. 42: 3251-3255 [Abstract] [Full Text]  
  • Telenti, A (1998). Genetics and pulmonary medicine bullet  5: Genetics of drug resistant tuberculosis. Thorax 53: 793-797 [Full Text]  
  • Schülin, T., Wennersten, C. B., Ferraro, M. J., Moellering, R. C. Jr., Eliopoulos, G. M. (1998). Susceptibilities of Legionella spp. to Newer Antimicrobials In Vitro. Antimicrob. Agents Chemother. 42: 1520-1523 [Abstract] [Full Text]  
  • Barrett, J. F., Goldschmidt, R. M., Lawrence, L. E., Foleno, B., Chen, R., Demers, J. P., Johnson, S., Kanojia, R., Fernandez, J., Bernstein, J., Licata, L., Donetz, A., Huang, S., Hlasta, D. J., Macielag, M. J., Ohemeng, K., Frechette, R., Frosco, M. B., Klaubert, D. H., Whiteley, J. M., Wang, L., Hoch, J. A. (1998). Antibacterial agents that inhibit two-component signal transduction systems. Proc. Natl. Acad. Sci. USA 95: 5317-5322 [Abstract] [Full Text]  
  • Murray, R. W., Schaadt, R. D., Zurenko, G. E., Marotti, K. R. (1998). Ribosomes from an Oxazolidinone-Resistant Mutant Confer Resistance to Eperezolid in a Staphylococcus aureus Cell-Free Transcription-Translation Assay. Antimicrob. Agents Chemother. 42: 947-950 [Abstract] [Full Text]  
  • Rybak, M. J., Cappelletty, D. M., Moldovan, T., Aeschlimann, J. R., Kaatz, G. W. (1998). Comparative In Vitro Activities and Postantibiotic Effects of the Oxazolidinone Compounds Eperezolid (PNU-100592) and Linezolid (PNU-100766) versus Vancomycin against Staphylococcus aureus, Coagulase-Negative Staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob. Agents Chemother. 42: 721-724 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»